Prolonged survival of patients with breast cancer-related leptomeningeal metastases

Anticancer Res. 2013 May;33(5):2057-63.

Abstract

Background/aim: Prolonged overall survival (OS) has been reported for selected patients with leptomeningeal metastases (LM). The management and treatment of such patients is poorly-described. We report our experience on breast cancer (BC)-associated LM and patients with prolonged survival.

Patients and methods: Eleven patients with BC and LM had an OS >12 months in which treatment is described.

Results: Combined intra-cerebro spinal fluid (CSF) and systemic treatment were administered until disease progression or toxicity in all but two patients. Involved-field radiotherapy was administered to two patients. Median OS in this selected cohort following LM diagnosis, was 21.0 (range=13-33.3) months.

Conclusion: Prolonged OS but also prolonged responses can be observed in BC with LM. An individualized and multi-disciplinary approach is advised for the management of these patients.

Keywords: Leptomeningeal metastases; breast cancer; intra-CSF chemotherapy; liposomal cytarabine; multimodality treatment; neoplastic meningitis.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy
  • Carcinoma, Ductal, Breast / mortality*
  • Carcinoma, Ductal, Breast / pathology
  • Carcinoma, Ductal, Breast / therapy
  • Carcinoma, Lobular / mortality*
  • Carcinoma, Lobular / pathology
  • Carcinoma, Lobular / therapy
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Meningeal Neoplasms / mortality*
  • Meningeal Neoplasms / secondary
  • Meningeal Neoplasms / therapy
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Survival Rate